Advancing Preclinical Oncology Studies with Novel Implantable Microdevices
Kibur Partnership Changes Oncology’s In Vivo Pharmacology Game
Our newest partnership with Kibur Medical brings translational technology to the preclinical oncology space with implantable microdevices (IMDs) that achieve significant cost and time savings in the process of drug discovery. Capable of holding up to 18 compounds, the device allows us to screen numerous candidates individually, in combination, or together with systemic treatments for their direct effects on tumor tissue.
In Vivo Pharmacology Screening with IMDs
The preloaded devices are placed directly within the tumor via minimally invasive needle injection. Programmed to deliver measured microdoses, drugs are administered to discrete regions of the tumor where effects can be measured. The IMD technology allows us to minimize the number of animals on a single study while maximizing the number of drugs screened, a significant advantage for the rapid, cost-effective evaluation of combination therapies that are often a successful approach to treating cancer patients.
The IMD technology finds its greatest translational value in combination with Charles River’s comprehensive portfolio of fully characterized patient-derived xenograft (PDX), cell line-derived, and syngeneic tumor models. Post treatment period, our expert oncology team excises the dosed tumor tissue for analysis via in-house multiplex immuno-histochemistry, immune cell readouts, spatial transcriptomics, and MALDI-TOF mass spectrometry
According to a study in Biostatistics, oncology drugs have a 97% failure rate in clinical trials. In vivo pharmacology studies that employ IMDs deliver rich datasets in short cycle times, driving better decisions early in the preclinical process. Dosing early stage compounds directly to tumor tissue, we gain a better understanding of their pharmacokinetic properties before advancing poor candidates further into development. Examining excised tumor tissue, we can also effectively measure the interactions of compounds and disease tissue, allowing us to better predict optimal drug doses or combination regimens.
The exciting partnership with Kibur Medical reflects our commitment to identify and implement new tools that accelerate your drug discovery and improve your drug development process.